AIDS.GOV | SERVICE LOCATOR | SEARCH

BLOG.AIDS.GOV

MENU

Treatment

FDA approves new treatment for HIV

FDA

The U.S. Food and Drug Administration today approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older. The CDC estimates that 1.2 million persons ages 13 years and older are living…

Every Dose, Every Day (TM): New Tool to Improve Medication Adherence

Every Dose Every Day image

Editor’s Note: The Centers for Disease Control has developed a new digital toolkit to promote medical adherence. This online resource includes a mobile app and can be used by providers as well as people living with HIV. CDC recently published the Every Dose, Every DayTM toolkit online. This toolkit offers assistance to both health care…

CDC Supports New WHO Early Release HIV Treatment and PrEP Guidelines

CDC Logo

For Immediate Release: Wednesday, September 30, 2015 Contact: Media Relations, Office of Communication (404) 639-3286 CDC welcomes today’s announcement by the World Health Organization (WHO) of new Early Release HIV Treatment and Pre-Exposure Prophylaxis (PrEP) guidelines that will significantly increase the number of people eligible for life-saving anti-retroviral treatment (ART) and expand access to a powerful…

Articles Highlight Ryan White HIV/AIDS Program Role Providing HIV Care and Treatment Services

ryan white 25 years rectangle

As the Ryan White HIV/AIDS Program (RWHAP) commemorates its 25th this summer, two new articles published this week highlight the critical role the Program has in providing care and treatment services to low income people living with HIV in the United States. According to a new article in the Journal of the American Medical Association,…

A Conversation with Dr. Anthony Fauci: Results from the START Trial and Implications for the Global Treatment of HIV

Anthony Fauci

Last week, NIH’s National Institute of Allergy and Infectious Diseases (NIAID) released the exciting results of the Strategic Timing of Antiretroviral Treatment (START) study, a randomized, controlled clinical trial to more clearly define the optimal time and benefits for people with HIV to begin antiretroviral therapy (ART). Given the implications of the study, AIDS.gov sat…

Starting antiretroviral treatment early improves outcomes for HIV-infected individuals

nih logo

For Immediate Release: Wednesday, May 27, 2015 NIH-funded trial results likely will impact global treatment guidelines A major international randomized clinical trial has found that HIV-infected individuals have a considerably lower risk of developing AIDS or other serious illnesses if they start taking antiretroviral drugs sooner, when their CD4+ T-cell count—a key measure of immune…

NIH’s Dr. Carl Dieffenbach Shares Highlights from First Day of CROI 2015 (Video)

Carl Dieffenbach - NIH - CROI2015

After the first full day of sessions at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI)  in Seattle yesterday, February 24, we caught up with Dr. Carl Dieffenbach, Director of the Division of AIDS at NIH’s National Institute of Allergy and Infectious Diseases (NIAID), to get his take on some of the key highlights of…

Let’s Get to Work!

Multi-Ethnic Group of People in a Meeting and Copy Space

In October, I attended the annual U.S. Conference on AIDS , the largest HIV/AIDS-related gathering in the nation. Now in its eighteenth year, the goal of this conference has remained steadfast since the start: to increase and strengthen the diversity of the nation’s response to the HIV/AIDS epidemic through education, training and collaboration. What has evolved…